Acro Biomedical Co annual stock-based compensation
2018
2019
2019
2020
2021
2022
2023
2024
Acro Biomedical Co Stock-Based Compensation Growth & History (ACBM)
Acro Biomedical Co's stock-based compensation was $0 for fiscal 2024.
View full Acro Biomedical Co company overviewAcro Biomedical Co annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $0 | −$8.1M | — |
| 2023 | 2023-12-31 | $8.1M | −$7.7M | −48.70% |
| 2022 | 2022-12-31 | $15.7M | $8.1M | +105.35% |
| 2021 | 2021-12-31 | $7.7M | $7.7M | — |
| 2020 | 2020-12-31 | $0 | −$148,395 | — |
| 2019 · Dec 31 | 2019-12-31 | $148,395 | — | — |
| 2019 · Sep 30 | 2019-09-30 | $300,089 | $292,678 | +3949.24% |
| 2018 | 2018-09-30 | $7,411 | — | — |
Acro Biomedical Co quarterly stock-based compensation
Q1.19
Q2.19
Q3.19
Q4.19
Q4.19
Q3.20
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $0 | $0 | — |
| Q4 2023 | 2023-12-31 | $0 | −$3.9M | — |
| Q3 2023 | 2023-09-30 | $1.0M | −$2.9M | −74.30% |
| Q2 2023 | 2023-06-30 | $3.1M | −$804,650 | −20.48% |
| Q1 2023 | 2023-03-31 | $3.9M | $0 | 0.00% |
| Q4 2022 | 2022-12-31 | $3.9M | — | — |
| Q3 2022 | 2022-09-30 | $3.9M | $1.0M | +34.59% |
| Q2 2022 | 2022-06-30 | $3.9M | — | — |
| Q1 2022 | 2022-03-31 | $3.9M | — | — |
| Q3 2021 | 2021-09-30 | $2.9M | $2.9M | — |
| Q3 2020 | 2020-09-30 | $0 | $0 | — |
| Q4 2019 | 2019-12-31 | $0 | −$151,694 | — |
| Q4 2019 · Sep 30 | 2019-09-30 | $0 | — | — |
| Q3 2019 | 2019-06-30 | $0 | — | — |
| Q2 2019 | 2019-03-31 | $148,395 | — | — |
| Q1 2019 | 2018-12-31 | $151,694 | — | — |
Acro Biomedical Co stock-based compensation trends
Over the last five fiscal years, Acro Biomedical Co's stock-based compensation decreased from $148,395 to $0, a change of −$148,395. The latest reported quarter, Q4 2024, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acro Biomedical Co source filings ↗